Drug Manufacturers Take Note: Oregon Proposes New Guidance Related to Price Reporting
The Oregon Department of Consumer and Business Services (the Department) issued a proposed bulletin on January 26 that seeks to provide guidance to drug manufacturers regarding the Department’s interpretation of what constitutes a “new prescription drug” for purposes of price reporting.
The proposed guidance clarifies that reporting requirements apply to both novel drugs and acquired drugs that meet the definition of “new prescription drug” and does not limit reporting requirements to the first labeler to market a particular new drug.
The proposed guidance may be found here.
Comments may be submitted on the proposed guidance, and must be received by Friday, February 26, 2021. Comments should be submitted to DFR.Bulletin@oregon.gov.
Contacts
- Related Industries